Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
February 3, 2017
Geneva, Switzerland – February 03, 2017 – ObsEva SA (ObsEva) announced today that Ernest LOUMAYE, M.D., Ph.D., CEO and Co-Founder and Tim ADAMS, CFO, will…
Read morepress release
January 25, 2017
(GLOBE NEWSWIRE via COMTEX) –ObsEva SA / ObsEva SA Announces Pricing of Initial Public Offering . Processed and transmitted by…
Read morepress release
January 17, 2017
Geneva, Switzerland, 17 January 2017 – ObsEva SA (ObsEva), a biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Read moreJune 29, 2023
May 18, 2022
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840